1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Opportunity Analyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024

Opportunity Analyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024

  • January 2016
  • 255 pages
  • ID: 3776354
In this report:


Table of Contents

Search Inside

Opportunity Analyzer: Hodgkin's Lymphoma - Opportunity Analysis and Estimations to 2024


Hodgkin's lymphoma, or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12.0 percent of all lymphomas and 0.60 percent of all additional cancer cases, but global prognosis is very good. However, treatment options for those patients who have failed first-line treatment are very few, and a serious unmet medical need remains in those patients. GlobalData estimated the HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.40B by 2024 at a Compound annual growth rate of 16%. This growth will be driven by label extensions for Adcetris, which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, including the immune checkpoint inhibitors, Opdivo and Keytruda. By the end of the forecast period, GlobalData expects Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a meaningful amount of the market. GlobalData anticipates that pipeline agents will have to show an efficacy advantage over currently used and inexpensive standard of care therapies. The challenge for additional entrants in the HL market is to meet the high unmet need of relapsed or refractory HL patients, reduce the long-term toxic side effects of current treatments, and improve global survival.

Key Findings

Key questions & answers

- Over the final forty years, only one targeted therapy has been approved for the treatment of HL - Adcetris. The HL space is now filled with excitement because Adcetris label extensions and approval of the first anti-PD-1 therapies are anticipated to change the treatment landscape. What will be the impact of these newly approved drugs on HL sales?

- With the success of molecular-targeted therapies, containing immune checkpoint inhibitors, across the oncology therapy area, what R&D strategies are being leveraged by firms to remain ambitious in the HL space?

- The survival of R/R HL patients remains poor, especially for those who fail transplant therapies. Therefore, there are considerably high unmet needs within this indication. What are the principal unmet needs remaining in this space? Will the drugs under development fulfil the unmet needs of the HL market?

Main highlights

- One of the principal drivers in the expansion of the HL market will be the label extensions of Adcetris in earlier lines of HL therapy, which will include the post-transplantation consolidation setting, as well as newly diagnosed advanced stage patients. The premium-priced anti-PD1-therapies, Opdivo and Keytruda, will also launch and be used in the treatment of the R/R HL population. These drugs are poised to partially meet the remaining unmet medical need of these hard-to-treat patients.

- Another driver of market increase will be the few players in the HL space; therefore, there is ample room for additional market entrants. A main driver will also be an increase in HL incidence due to an increasing population. This will lead to an global increase of the number of drug-treatable HL patients, and market value.

- Corporations are focusing on the development of therapies targeting the R/R HL population, hoping to expedite the route to market for their pipeline products, and improving the integrated remission rate and duration of remission of these patients.

- One of the biggest unmet needs is that of the newly diagnosed advanced stage HL population. Other unmet needs contain the high proportion of patients failing transplant therapies and the toxicity of second-line treatment options.


- Overview of HL, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, disease management, and current treatment options.

- Top-line HL therapeutics market revenue from 2014-2024. Average cost of therapy and main pipeline product sales in this forecast period are included.

- Key topics covered include tactical competitor assessment, market characterization, unmet needs, R&D strategies, and clinical trial design for the HL market.

- Pipeline analysis: exhaustive data split across distinct phases, emerging novel trends under development, synopses of innovative early-stage projects, and in-depth analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

- Analysis of the current and future market competition in the overall HL market. Insightful review of the top industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Great reasons to purchase

The market research will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most strong pipeline.

- Develop strategic management by understanding the trends shaping and driving the overall HL market.

- Drive revenues by understanding the main trends, innovative products and technologies, market segments, and firms likely to impact the overall HL market in the outlook.

- Specified effective sales and marketing strategies by understanding the challenging landscape and by analysing the performance of different competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a ambitious advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and tactical partnerships.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
TNF Inhibitors - A Pipeline Analysis Report

TNF Inhibitors - A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

TNF Inhibitors: An insightThe TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global ...

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

Stem Cell Therapy for Diabetes and Related Conditions - A Pipeline Analysis Report

  • $ 3500
  • Industry report
  • October 2017
  • by Infiniti Research Limited

Stem cell therapy for diabetes and related conditions: An insightThe stem cell therapy for diabetes and related conditions pipeline analysis report includes ongoing clinical and non-clinical trends in ...

Plasma Protease C1-inhibitor Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

Plasma Protease C1-inhibitor Treatment Industry: Forecasts to 2025

  • $ 5795
  • Industry report
  • October 2017
  • by Transparency Market Research

Global Plasma Protease C1-inhibitor Treatment Market: OverviewThis report on the plasma protease C1-inhibitors treatment market analyzes the current and future scenario of the global market. Large numbe ...


Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.